GlassScriptPhysician profile
Kari Anglin
NPI 1649712183
$12,992.56
in general payments reported to CMS, 2019-2025
16 companies · $3,438 in 2025
The $3,438 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $641 · 2022: $544 · 2023: $5,178 · 2024: $3,191 · 2025: $3,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,399 · Travel and Lodging: $3,696 · Consulting Fee: $2,190 · Education: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,399.12 |
| Travel and Lodging | $3,695.82 |
| Consulting Fee | $2,190.00 |
| Education | $522.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,098.89 | 2021-2025 | Percept PC Brainsense, Activa PC |
| Mdd US Operations, LLC | $2,842.24 | 2023-2025 | Gocovri, Apokyn |
| Abbvie INC. | $2,048.26 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $1,003.66 | 2022-2025 | Nuplazid |
| Boston Scientific Corporation | $764.84 | 2021-2025 | Vercise, General - Dbs |
| Teva Pharmaceuticals USA, INC. | $753.91 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Kyowa Kirin, INC. | $526.06 | 2021-2024 | Nourianz |
| Supernus Pharmaceuticals, INC. | $466.78 | 2023-2025 | Qelbree |
| Alexion Pharmaceuticals, INC. | $384.99 | 2021-2024 | Ultomiris |
| Abbott Laboratories | $347.36 | 2023-2025 | Infinity |
| Amneal Pharmaceuticals LLC | $340.42 | 2024-2025 | Crexont |
| Jazz Pharmaceuticals INC. | $121.83 | 2024 | |
| Revance Therapeutics, INC. | $115.64 | 2024 | Daxxify |
| Sunovion Pharmaceuticals INC. | $71.54 | 2022 | |
| Acorda Therapeutics, INC | $69.65 | 2023-2024 | Inbrija |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $36.49 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Anglin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.